SNDX logo

Syndax Pharmaceuticals, Inc.


SNDX: Syndax Pharmaceuticals Inc is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States.


Show SNDX Financials

Consumer Interest
SEC Filings

Recent trades of SNDX by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard

Recently reported changes by institutional investors

Quarterly net insider trading by SNDX's directors and management

Government lobbying spending instances

  • $20,000 Aug 12, 2020 Issue: Health Issues Government Issues
  • $80,000 Jul 19, 2020 Issue: Health Issues Government Issues
U.S. Patents

New patents grants

  • Patent Title: Selection of patients for combination therapy Jul. 26, 2022
  • Patent Title: Combination of hdac inhibitor and anti-pd-1 antibody for treatment of cancer May. 10, 2022
  • Patent Title: Methods for the treatment of breast cancer Mar. 12, 2019
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard

Number of mentions of SNDX in WallStreetBets Daily Discussion


Recent insights relating to SNDX

CNBC Recommendations

Recent picks made for SNDX stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in SNDX

Corporate Flights

Flights by private jets registered to SNDX